These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36939549)

  • 1. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biologics in uveitis].
    Feurer E; Bielefeld P; Saadoun D; Sève P
    Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.
    Silvestri E; Bitossi A; Bettiol A; Emmi G; Urban ML; Mattioli I; Di Scala G; Bacherini D; Lopalco G; Venerito V; Iannone F; Vitale A; Tosi GM; Rizzo S; Fabiani C; Cantarini L; Virgili G; Vannozzi L; Prisco D
    Inflammopharmacology; 2020 Jun; 28(3):711-718. PubMed ID: 32157555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Modorati G; Berchicci L; Pontikaki I; Meroni P; Gerloni V
    Br J Ophthalmol; 2016 Jun; 100(6):782-6. PubMed ID: 26396026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
    Pasadhika S; Rosenbaum JT
    Biologics; 2014; 8():67-81. PubMed ID: 24600203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
    Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.
    Urruticoechea-Arana A; Cobo-Ibáñez T; Villaverde-García V; Santos Gómez M; Loza E; Vargas-Osorio K; Fariñas Padrón L; Diaz-Gonzalez F; Calvo-Río V; Blanco R
    Rheumatol Int; 2019 Jan; 39(1):47-58. PubMed ID: 30421105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
    Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
    Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):517-534. PubMed ID: 29773271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic advances in juvenile idiopathic arthritis - associated uveitis.
    Gueudry J; Touhami S; Quartier P; Bodaghi B
    Curr Opin Ophthalmol; 2019 May; 30(3):179-186. PubMed ID: 30844943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing biologic options for the management of Behcet's disease-related uveitis.
    Vitale A; Caggiano V; Berlengiero V; Perfetti MO; Sota J; Tosi GM; Frediani B; Cantarini L; Fabiani C
    Expert Rev Clin Immunol; 2023 Mar; 19(3):315-328. PubMed ID: 36715297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy in relapsing polychondritis: navigating between options.
    Padoan R; Campaniello D; Iorio L; Doria A; Schiavon F
    Expert Opin Biol Ther; 2022 May; 22(5):661-671. PubMed ID: 35230215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.